Pulse Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $350.0K | $0 | $0 | $700.0K | $1.4M | $0 |
| Cost of Revenue | $539.0K | $0 | $0 | $11.9M | $2.0M | $0 |
| Gross Profit | $-189.0K | $0 | $0 | $-11.2M | $-550.0K | $0 |
| Gross Margin | -54.0% | — | — | -1,606.3% | -38.8% | — |
| Operating Expenses | ||||||
| Research & Development | $44.7M | $32.3M | $27.8M | $20.8M | $28.6M | $26.4M |
| SG&A Expense | $32.0M | $23.9M | $15.8M | $14.0M | $19.1M | $16.3M |
| Operating Income | $-76.9M | $-56.3M | $-43.6M | $-58.1M | $-63.0M | $-50.0M |
| Operating Margin | -21,982.6% | — | — | -8,293.9% | -4,443.9% | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $72.8M | $53.6M | $-42.2M | $-58.5M | $-63.7M | $-49.9M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-72.8M | $-53.6M | $-42.2M | $-58.5M | $-63.7M | $-49.9M |
| Net Margin | -20,794.6% | — | — | -8,357.9% | -4,489.4% | — |
| EPS (Basic) | $-1.08 | $-0.92 | $-0.85 | $-1.72 | $-2.28 | $-2.14 |
| EPS (Diluted) | — | — | — | — | $-2.28 | $-2.14 |
| Shares Outstanding (Basic) | 67.4M | 58.4M | 49.7M | 33.9M | 28.0M | 23.2M |
| Shares Outstanding (Diluted) | 67.4M | 58.4M | 49.7M | 33.9M | 28.0M | 23.2M |
| Dividends Per Share | — | — | — | — | — | — |